TD Cowen lowered the firm’s price target on Standard BioTools (LAB) to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard BioTools Inc. Reports Q3 2025 Financial Results
- Cautious Hold Rating for Standard BioTools Amid Economic Challenges and Uncertain Strategic Outlook
- Standard BioTools Implements Restructuring for Future Growth
- LAB Upcoming Earnings Report: What to Expect?
- Standard BioTools Announces Workforce Reduction Plan